RK Asset Management LLC Has $4.57 Million Stake in Opko Health Inc. (OPK)
RK Asset Management LLC lifted its holdings in shares of Opko Health Inc. (NASDAQ:OPK) by 8.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 932,752 shares of the biotechnology company’s stock after purchasing an additional 72,209 shares during the quarter. Opko Health comprises about 3.9% of RK Asset Management LLC’s investment portfolio, making the stock its 12th biggest position. RK Asset Management LLC owned about 0.17% of Opko Health worth $4,570,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Belpointe Asset Management LLC acquired a new position in Opko Health in the third quarter valued at $583,000. Cornerstone Capital Management Holdings LLC. boosted its holdings in Opko Health by 611.8% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 1,445,310 shares of the biotechnology company’s stock valued at $9,913,000 after acquiring an additional 1,242,272 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Opko Health by 127.2% in the third quarter. Dimensional Fund Advisors LP now owns 4,003,643 shares of the biotechnology company’s stock valued at $27,466,000 after acquiring an additional 2,241,103 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Opko Health by 43.0% in the third quarter. Schwab Charles Investment Management Inc. now owns 1,566,433 shares of the biotechnology company’s stock valued at $10,746,000 after acquiring an additional 471,256 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in Opko Health by 14.3% in the third quarter. Wells Fargo & Company MN now owns 481,085 shares of the biotechnology company’s stock valued at $3,300,000 after acquiring an additional 60,177 shares during the last quarter. Institutional investors and hedge funds own 22.90% of the company’s stock.
In other Opko Health news, major shareholder Opko Health, Inc. bought 655,738 shares of the company’s stock in a transaction dated Monday, October 30th. The shares were acquired at an average cost of $3.05 per share, with a total value of $2,000,000.90. Following the completion of the transaction, the insider now owns 6,678,752 shares in the company, valued at $20,370,193.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 40.19% of the company’s stock.
A number of brokerages recently weighed in on OPK. Zacks Investment Research cut Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. BidaskClub upgraded Opko Health from a “sell” rating to a “hold” rating in a report on Saturday, September 23rd. JPMorgan Chase & Co. cut Opko Health from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $12.00 to $7.00 in a report on Thursday, September 14th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $16.00 target price on shares of Opko Health in a report on Monday, September 25th. Finally, Cantor Fitzgerald set a $20.00 price objective on Opko Health and gave the company a “buy” rating in a research report on Wednesday, October 25th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $13.34.
Opko Health Inc. (NASDAQ:OPK) opened at $5.07 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.48. Opko Health Inc. has a 52-week low of $4.50 and a 52-week high of $9.55. The company has a market capitalization of $2,864.15, a PE ratio of -23.05 and a beta of 1.82.
Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.03). Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The company had revenue of $263.50 million during the quarter, compared to analysts’ expectations of $319.43 million. During the same period last year, the business earned ($0.03) earnings per share. The company’s revenue for the quarter was down 11.6% compared to the same quarter last year. equities research analysts anticipate that Opko Health Inc. will post -0.27 EPS for the current fiscal year.
Opko Health Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health Inc. (NASDAQ:OPK).
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with Analyst Ratings Network's FREE daily email newsletter.